Next Article in Journal
The Glutathione Derivative, GSH Monoethyl Ester, May Effectively Whiten Skin but GSH Does Not
Next Article in Special Issue
Site-Specific Integration of Exogenous Genes Using Genome Editing Technologies in Zebrafish
Previous Article in Journal
Protective Effect of Tyrosol and S-Adenosylmethionine against Ethanol-Induced Oxidative Stress of Hepg2 Cells Involves Sirtuin 1, P53 and Erk1/2 Signaling
Previous Article in Special Issue
Genome Editing in C. elegans and Other Nematode Species
Open AccessReview

In Vivo Delivery Systems for Therapeutic Genome Editing

by Luyao Wang 1,†, Fangfei Li 1,†, Lei Dang 1,†, Chao Liang 1, Chao Wang 1, Bing He 1, Jin Liu 1, Defang Li 1, Xiaohao Wu 1, Xuegong Xu 2,*, Aiping Lu 1,* and Ge Zhang 1,*
1
Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 00852, China
2
Central Laboratory, Zheng Zhou Hospital of Traditional Chinese Medicine, Zhengzhou 450000, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Izuho Hatada
Int. J. Mol. Sci. 2016, 17(5), 626; https://doi.org/10.3390/ijms17050626
Received: 15 February 2016 / Revised: 11 April 2016 / Accepted: 14 April 2016 / Published: 27 April 2016
(This article belongs to the Special Issue Genome Editing)
Therapeutic genome editing technology has been widely used as a powerful tool for directly correcting genetic mutations in target pathological tissues and cells to cure of diseases. The modification of specific genomic sequences can be achieved by utilizing programmable nucleases, such as Meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regularly-interspaced short palindromic repeat-associated nuclease Cas9 (CRISPR/Cas9). However, given the properties, such as large size, negative charge, low membrane penetrating ability, as well as weak tolerance for serum, and low endosomal escape, of these nucleases genome editing cannot be successfully applied unless in vivo delivery of related programmable nucleases into target organisms or cells is achieved. Here, we look back at delivery strategies having been used in the in vivo delivery of three main genome editing nucleases, followed by methodologies currently undergoing testing in clinical trials, and potential delivery strategies provided by analyzing characteristics of nucleases and commonly used vectors. View Full-Text
Keywords: in vivo delivery systems; vectors; genome editing; programmable nucleases in vivo delivery systems; vectors; genome editing; programmable nucleases
Show Figures

Figure 1

MDPI and ACS Style

Wang, L.; Li, F.; Dang, L.; Liang, C.; Wang, C.; He, B.; Liu, J.; Li, D.; Wu, X.; Xu, X.; Lu, A.; Zhang, G. In Vivo Delivery Systems for Therapeutic Genome Editing. Int. J. Mol. Sci. 2016, 17, 626.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop